Acamprosate calcium - CAS 77337-73-6
Not Intended for Therapeutic Use. For research use only.
Product Name:
Acamprosate calcium
Catalog Number:
Calcium 3-acetamidopropane-1-sulfonate;Calcium 3-(acetylamino)propanesulphonate;3-(Acetylamino)-1-propanesulfonic Acid Calcium Salt;Calcium Acetylhomotaurine ;Alcomed;Sobriol;Aotal calcium;Calcium N-acetylhomotaurinate
CAS Number:
Acamprosate calcium is a gamma-aminobutyric acid(GABA)agonist and modulator of glutamatergic systems. It has been used in alcohol dependence treatments and may be an effective augmentation therapy in patients with treatment-resistant anxiety. It has low bioavailability, but also has an excellent tolerability and safety profile. It is unique in that it is not metabolized by the liver and is also not impacted by alcohol use, so it can be administered to patients with hepatitis or liver disease and to patients who continue drinking alcohol. It was approved for use in the therapy of alcohol dependence and abuse in the United States in 2004.
Molecular Weight:
Molecular Formula:
Grams to Kilograms
Quality Standard:
In-house standard
Canonical SMILES:
GABA Receptor
Current Developer:
It has been approved the listing.
Chemical Structure
CAS 77337-73-6 Acamprosate calcium

Related GABA Receptor Products

CAS 54-95-5 Cardiazole

(CAS: 54-95-5)

Cardiazole is a GABA(A) receptor antagonist, causes alterations in excitatory and inhibitory neurotransmitter systems.

CAS 325715-02-4 Indiplon

(CAS: 325715-02-4)

Indiplon acts as a high-affinity positive and orally active allosteric modulator of the GABAA receptor (Ki=1.2 nM in rat frontal cortex and Ki=1.7 nM and in cer...

CAS 64603-91-4 Gaboxadol

(CAS: 64603-91-4)

Gaboxadol is a GABA agonist. It was a non-opioid analgesic and a novel type of hypnotic. It was first synthesized in 1977 by the Danish chemist Povl Krogsgaard-...

CAS 15291-75-5 Ginkgolide A

Ginkgolide A
(CAS: 15291-75-5)

Ginkgolide A is an extract from in Ginkgo biloba and a g-aminobutyric acid (GABA) antagonist with a Ki of 14.5 μM.

(CAS: 194098-25-4)

CP-409092 is a GABA(A) partial agonist developed for the treatment of General Anxiety Disorder (GAD) and presents an interesting phenomenon of human pharmacokin...

CAS 56776-32-0 Etifoxine Hydrochloride

Etifoxine Hydrochloride
(CAS: 56776-32-0)

Etifoxine Hydrochloride is Potentiator of GABAA receptor with anxiolytic and anticonvulsant activity.

CAS 77337-73-6 Acamprosate calcium

Acamprosate calcium
(CAS: 77337-73-6)

Acamprosate calcium is a gamma-aminobutyric acid(GABA)agonist and modulator of glutamatergic systems. It has been used in alcohol dependence treatments and may ...

GS 39783
(CAS: 39069-52-8)

GS 39783 is an allosteric positive modulator of GABAB receptors, decreases cocaine self-administration, blocks the rewarding properties of nicotine and produces...

CAS 57717-80-3 CGP7930

(CAS: 57717-80-3)

CGP7930 is a positive allosteric modulator at the GABAB receptor. It has anxiolytic effects in animal studies, and has a synergistic effect with GABAB agonists ...

CAS 63701-55-3 Arbaclofen Hydrochloride

Arbaclofen Hydrochloride
(CAS: 63701-55-3)

Arbaclofen, the R-enantiomer of baclofen, is a selective gamma-amino butyric acid type B receptor agonist used for autism spectrum disorder and fragile X syndro...

CAS 33125-97-2 Etomidate

(CAS: 33125-97-2)

Etomidate is a GABAA receptor agonist, used as a short-acting anaesthetic agent or sedative.

CAS 56287-74-2 Afloqualone

(CAS: 56287-74-2)

Afloqualone is a agonist of GABA receptor has sedative and muscle-relaxant effects.

CAS 77191-36-7 Nefiracetam

(CAS: 77191-36-7)

Nefiracetam is a GABAergic, cholinergic, and monoaminergic neuronal system enhancer for Ro 5-4864-induced convulsions.

CAS 130477-52-0 L-655,708

(CAS: 130477-52-0)

L-655,708, an inverse agonist of α5 subunit involved in GABAA receptor, has been found to exhibit cognitive performance improvement in biological studies.

CGP 52432
(CAS: 139667-74-6)

CGP52432 is a potent and selective GABAB receptor antagonist with IC50 value of 85 nM.

(CAS: 733717-87-8)

CH-50911 is a selective GABA-B antagonist with IC50 value of 1.1 μM. It is developed by Schering-Plough Corporation. CH-50911 is often used in pharmacology rese...

(CAS: 164025-33-6)

PWZ-029, a benzodiazepine derivative, has been found to be a GABAA receptors inverse agonist that could probably improve memory and exhibit sedative effects at ...

CGP 54626 hydrochloride
(CAS: 149184-21-4)

The hydrochloride salt form of CGP 54626, a dichloropheny derivative, has been found to be a GABAB receptor antagonist that could probably be effective as an an...

Remimazolam benzenesulfonat
(CAS: 1001415-66-2)

Remimazolam, a novel Benzodiazepine derivatives, has potential use for anxiolytic, sedative and hypnotic. For the reason that remimazolam's beding discontinued ...

CAS 62666-20-0 Progabide

(CAS: 62666-20-0)

Progabide is a gamma-aminobutyric acid (GABA) antagonist. It has agonistic activity for both the GABAA and GABAB receptors. It has antiepileptic activity and is...

Reference Reading

1.Modulation of learning and memory by natural polyamines.
Guerra GP1, Rubin MA2, Mello CF3. Pharmacol Res. 2016 Mar 22. pii: S1043-6618(16)30189-X. doi: 10.1016/j.phrs.2016.03.023. [Epub ahead of print]
Spermine and spermidine are natural polyamines that are produced mainly via decarboxylation of l-ornithine and the sequential transfer of aminopropyl groups from S-adenosylmethionine to putrescine by spermidine synthase and spermine synthase. Spermine and spermidine interact with intracellular and extracellular acidic residues of different nature, including nucleic acids, phospholipids, acidic proteins, carboxyl- and sulfate-containing polysaccharides. Therefore, multiple actions have been suggested for these polycations, including modulation of the activity of ionic channels, protein synthesis, protein kinases, and cell proliferation/death, within others. In this review we summarize these neurochemical/neurophysiological/morphological findings, particularly those that have been implicated in the improving and deleterious effects of spermine and spermidine on learning and memory of naïve animals in shock-motivated and nonshock-motivated tasks, from a historical perspective.
2.Potential Medications for the Treatment of Alcohol Use Disorder: An Evaluation of Clinical Efficacy and Safety.
Litten RZ1, Wilford BB2, Falk DE1, Ryan ML1, Fertig JB1. Subst Abus. 2016 Feb 29:0. [Epub ahead of print]
Alcohol use disorder (AUD), as currently defined in the Diagnostic and Statistical Manual, Fifth Edition (DSM-5), is a heterogeneous disorder stemming from a complex interaction of neurobiological, genetic, and environmental factors. As a result of this heterogeneity, there is no one treatment for AUD that will work for everyone. During the past two decades, efforts have been made to develop a menu of medications to give patients and clinicians more choices when seeking a therapy that is both effective and which has limited side effects. To date, three medications have been approved by the U.S. Food and Drug Administration (FDA) to treat alcohol dependence: disulfiram, naltrexone, and acamprosate. In addition to these approved medications, researchers have identified new therapeutic targets and, as a result, a number of alternative medications are now being evaluated for treatment of AUD in human studies. Although not approved by the FDA for the treatment of AUD, in some cases, these alternative medications are being used off-label by clinicians for this purpose.
3.Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.
Sinclair JM1,2, Chambers SE3, Shiles CJ3,4, Baldwin DS3,5. Drug Saf. 2016 Mar 29. [Epub ahead of print]
Alcohol use disorders (AUD) cause significant morbidity and mortality worldwide, but pharmacological treatments for them are underused, despite evidence of efficacy. Acamprosate, naltrexone, nalmefene and disulfiram are all approved in one or more region for the treatment of AUD. Baclofen currently has a temporary indication in France. Safety considerations for using psychopharmacological treatments in this patient group include the impact of concurrent alcohol consumption at high levels; multiple physical comorbidities that may interfere with pharmacological effects, distribution and metabolism; and concomitant medication for the treatment of comorbid physical and psychiatric conditions. The five drugs, including an extended-release injectable suspension of naltrexone, have different safety profiles that need to be balanced with the treatment objective (initiation or continuation of abstinence, or reduction of drinking), individual patient preferences and comorbid conditions.
4.Alcoholic liver disease and hepatitis C virus infection.
Novo-Veleiro I1, Alvela-Suárez L1, Chamorro AJ1, González-Sarmiento R1, Laso FJ1, Marcos M1. World J Gastroenterol. 2016 Jan 28;22(4):1411-20. doi: 10.3748/wjg.v22.i4.1411.
Alcohol consumption and hepatitis C virus (HCV) infection have a synergic hepatotoxic effect, and the coexistence of these factors increases the risk of advanced liver disease. The main mechanisms of this effect are increased viral replication and altered immune response, although genetic predisposition may also play an important role. Traditionally, HCV prevalence has been considered to be higher (up to 50%) in alcoholic patients than in the general population. However, the presence of advanced alcoholic liver disease (ALD) or intravenous drug use (IDU) may have confounded the results of previous studies, and the real prevalence of HCV infection in alcoholic patients without ALD or prior IDU has been shown to be lower. Due to the toxic combined effect of HCV and alcohol, patients with HCV infection should be screened for excessive ethanol intake. Patients starting treatment for HCV infection should be specifically advised to stop or reduce alcohol consumption because of its potential impact on treatment efficacy and adherence and may benefit from additional support during antiviral therapy.